Trial Management Group

Trial Activation

This is to inform you that IND.200 -- A phase II study of SB939 in patients with translocation-associated recurrent/metastatic sarcomas -- was centrally activated 18 March 2010. http://www.ctg.queensu.ca/trials/ind/i200/200.html